Aurinia Pharmaceuticals doses first participant in AUR200 trial

Aurinia Pharmaceuticals announced that the first participant has been dosed in a Phase 1a single ascending dose study of AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF – B-cell Activating Factor – and APRIL – A Proliferation-Inducing Ligand -. The SAD study will assess the safety, tolerability, pharmacokinetics, and changes in biomarkers for AUR200 in healthy volunteers, with data expected in the first half of 2025. The company intends to develop AUR200 in disease states where there are currently few market entrants, including one larger indication and one fast-to-market smaller indication that meets the FDA criteria for orphan and rare diseases. The company anticipates funding this development program with available cash flow, which is not anticipated to impact previously announced post-restructuring operating expense targets.